127105-49-1

Basic information

• Product Name: METHYL (S)-2-AMINO-4-(1H-TETRAZOL-5-YL)BUTYRATE
• Synonyms: METHYL (S)-2-AMINO-4-(1H-TETRAZOL-5-YL)BUTYRATE
• CAS NO: 127105-49-1
• Molecular Formula: C₆H₁₁N₅O₂
• Molecular Weight: 0
• Mol File: 127105-49-1.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: METHYL (S)-2-AMINO-4-(1H-TETRAZOL-5-YL)BUTYRATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL (S)-2-AMINO-4-(1H-TETRAZOL-5-YL)BUTYRATE(127105-49-1)
• EPA Substance Registry System: METHYL (S)-2-AMINO-4-(1H-TETRAZOL-5-YL)BUTYRATE(127105-49-1)

Safety Data

• Hazardous Substances Data: 127105-49-1(Hazardous Substances Data)

Upstream product

• 65882-90-8 methyl (2S)-2-(benzyloxycarbonylamino)-4-(tetrazol-5-yl)butyrate 

Downstream Products

• 247904-63-8 (S)-2-[4-[N-[[3,4-dihydro-2,7-dimethyl-4-oxo-3-[(pivaloyloxy)methyl]-6-quinazolinyl]methyl]-N-prop-2-ynylamino]-2-fluorobenzamido]-4-(1H-1,2,3,4-tetrazol-5-yl)butyric acid methyl ester 
• 30134-53-3 S-4-Cyano-2-[[(phenylmethoxy)carbonyl]-amino]butanoic acid methyl ester 

Relevant articles and documents

Quinazoline thymidylate synthase inhibitors

The invention relates to quinazoline derivatives or pharceutically-acceptable salts thereof, which possess anti-tumor activity; to processes for their manufacture; and to pharmaceutical compositions containing them. The invention provides a quinazoline of the formula: STR1 wherein R1 is (1-4C)alkyl; the quinazoline ring may optionally bear one or two further substituents selected from halogeno, (1-4C)alkyl and (1-4C)alkoxy; R2 is hydrogen or (1-4C)alkyl; R3 includes hydrogen and (1-4C)alkyl; and Ar is optionally substituted phenylene or heterocyclene; or a pharmaceutically-acceptable salt or ester thereof.

Tricyclic compounds with pharmaceutical activity

The invention relates to tricyclic compounds of formula (I) STR1 wherein R1 is hydrogen, amino, (1-4C)alkyl, (1-4C)alkoxy, hydroxy-(1-4C)alkyl or fluoro-(1-4C)alkyl; R2 is hydrogen, (1-4C)alkyl, (3-4C)alkenyl, (3-4C)alkynyl, hydroxy-(2-4C)alkyl, halogeno-(2-4C)alkyl or cyano-(1-4C)alkyl; Ar is optionally-substituted phenylene, thiophenediyl, thiazolediyl, pyridinediyl or pyrimidinediyl; and R3 includes a group of the formula --NHCH(CO2 H)--A1 --Y1 wherein A1 is (1-6C)alkylene and Y1 is carboxy, tetrazol-5-yl, N-?(1-4C)alkylsulphonyl!carbamoyl, N(phenylsulphonyl)carbamoyl, tetrazol-5-ylthio, tetrazol-5-ylsulphinyl or tetrazol-5-ylsulphonyl; or pharmaceutically-acceptable salts or esters thereof; to processes for their manufacture; to pharmaceutical compositions containing them; and to their use as anti-cancer agents.

Non-glutamate type pyrrolo[2,3-d]pyrimidine antifolates. I: Synthesis and biological properties of pyrrolo[2,3-d]pyrimidine antifolates containing tetrazole congener of glutamic acid

Either the α- or γ-carboxyl group of the glutamic acid moiety of N-[4-[3-(2,4-diamino-7H-pyrrolo[2,3-d]pyrimidin-5-yl)propyl] benzoyl]-L-glutamic acid (1b, TNP-351) and its related compound (1a) was replaced with a 1H-tetrazole ring, and the in